Inhibrx Historical Cash Flow
| INBX Stock | USD 15.63 0.18 1.17% |
Analysis of Inhibrx cash flow over time is an excellent tool to project Inhibrx future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 26.1 M or Change In Working Capital of 16.1 M as it is a great indicator of Inhibrx ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Inhibrx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inhibrx is a good buy for the upcoming year.
Inhibrx |
About Inhibrx Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Inhibrx balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Inhibrx's non-liquid assets can be easily converted into cash.
Inhibrx Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Inhibrx to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Inhibrx operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Change Receivables
The difference in the amount of accounts receivable from one accounting period to the next. A positive number indicates an increase in receivables, while a negative number indicates a decrease.Most accounts from Inhibrx's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Inhibrx current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.At this time, Inhibrx's Issuance Of Capital Stock is fairly stable compared to the past year. Change Receivables is likely to rise to about 749.9 K in 2024, whereas Change In Cash is likely to drop slightly above 3.9 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Sale Purchase Of Stock | 43.8M | 129.7M | 116.8M | 82.8M | Issuance Of Capital Stock | 40.2M | 127.4M | 200M | 210M |
Inhibrx cash flow statement Correlations
Click cells to compare fundamentals
Inhibrx Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Inhibrx cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 9.4M | 117.1M | 2.6M | 142.6M | 4.1M | 3.9M | |
| Net Borrowings | 33.8M | 41.4M | 40.0M | 128.9M | 148.2M | 155.6M | |
| Stock Based Compensation | 4.0M | 5.0M | 15.0M | 17.8M | 24.8M | 26.1M | |
| Free Cash Flow | (33.9M) | (49.3M) | (81.2M) | (116.0M) | (197.9M) | (188.0M) | |
| Change In Working Capital | 3.5M | 12.7M | (17.5M) | 3.2M | 15.3M | 16.1M | |
| Begin Period Cash Flow | 2.1M | 11.5M | 128.7M | 131.3M | 273.9M | 287.6M | |
| Total Cashflows From Investing Activities | (1.8M) | (1.4M) | (809K) | (686K) | (617.4K) | (648.3K) | |
| Other Cashflows From Financing Activities | 37.5M | 166.5M | 83.8M | 128.8M | 202.0M | 212.1M | |
| Depreciation | 1.2M | 1.0M | 1.2M | 1.2M | 1.2M | 979.1K | |
| Other Non Cash Items | 9.6M | 11.6M | 2.7M | 5.1M | 6.7M | 4.6M | |
| Capital Expenditures | 1.8M | 1.4M | 864K | 686K | 4.6M | 4.8M | |
| Total Cash From Operating Activities | (32.1M) | (48.0M) | (80.3M) | (115.3M) | (193.3M) | (183.6M) | |
| Change To Operating Activities | (2.5M) | 7.8M | (11.0M) | 5.7M | 6.6M | 6.9M | |
| Net Income | (51.4M) | (76.1M) | (81.8M) | (145.2M) | (241.4M) | (229.3M) | |
| Total Cash From Financing Activities | 43.3M | 166.5M | 83.8M | 258.6M | 202.0M | 111.3M | |
| End Period Cash Flow | 11.5M | 128.7M | 131.3M | 273.9M | 277.9M | 291.8M | |
| Change To Netincome | 6.4M | 4.3M | 16.5M | 20.5M | 23.5M | 24.7M | |
| Change To Liabilities | 5.5M | 4.8M | (6.3M) | 6.9M | 7.9M | 8.3M | |
| Change To Inventory | (672K) | (2.5M) | 7.8M | (11.0M) | (9.9M) | (9.4M) | |
| Investments | (1.8M) | (1.4M) | (809K) | (686K) | (4.6M) | (4.4M) | |
| Change To Account Receivables | 491K | 117K | (167K) | 130K | (521K) | (495.0K) | |
| Issuance Of Capital Stock | 12M | 136.9M | 40.2M | 127.4M | 200M | 210M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.